CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with glatiramer acetate (Copaxone)

Folia Neuropathologica

Volumn 43, Issue 3, 2005, Pages 153-155

  Losy, Jacek ^a,b   Michałowska Wender, Grazyna ^a,b   Kudryńska, Aleksandra ^b   Wender, Mieczysław ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Copaxone; MCP 1; Multiple sclerosis; RANTES

Indexed keywords

BETA1A INTERFERON; CYTOKINE; GLATIRAMER; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; LONG TERM CARE; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

EID: 27844526135     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Franciotta D, Martino C, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-198.
2. Iarlori C, Reale M, Lugaresi A, De Luca C, Bonanni L, Di Iorio A, Feliciani C, Conti P, Gambi D. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol 2000; 107: 100-107.
3. Khoury S. Immunologic basic of MS. Cokk S (ed). Handbook of multiple sclerosis. Dekker, New York 1990.
4. Losy J, Michałowska-Wender C, Wender M. Analysis of interleukin 18 during therapy with glatiramer acetate (Copaxone) in patients with relapsing-remitting multiple sclerosis. Folia Neuropathol 2001; Suppl. A: 23-24.
5. Losy J, Michałowska-Wender G, Wender M. Interleukin 12 and interleukin 10 are affected differentially by treatment of multiple sclerosis with glatiramer acetate (Copaxone). Folia Neuropathol 2002; 40: 173-175.
6. Mc Donald WI, Compston A. Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnostic of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
7. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113-121.
8. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers CC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1993; 13: 227-231.
9. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004; 63, Suppl. 6: 8-14.
10. Sindern E, Niederkinkhaus Y, Henschel M, Ossege LM, Patzold T, Malin JP. Differential release of -chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2001; 104: 88-91.
11. Sörensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 2001; 8: 665-672.